SCHEMBL1998019

SCHEMBL1998019

O=C(Nc1ccc(-c2nc3ccc(O)cc3s2)cc1)c1ccc(F)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 7/20 0.70
SULT1A1 P50225 3/20 0.70
MAPT P10636 2/20 0.59
MMP2 P08253 1/20 0.59
MMP9 P14780 1/20 0.59
MMP8 P22894 1/20 0.59
MMP13 P45452 1/20 0.59
LMNA P02545 1/20 0.57
DYRK1A Q13627 1/20 0.55
PTPN11 Q06124 1/20 0.55
HDAC3 O15379 1/20 0.55
HDAC1 Q13547 1/20 0.55
HDAC2 Q92769 1/20 0.55
HDAC8 Q9BY41 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
MAOB P27338 1/20 0.55
PTPN1 P18031 1/20 0.53
MGAM O43451 1/20 0.53
HSD17B1 P14061 1/20 0.52
HSD17B2 P37059 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2192885 0.89 APP (0.70) APPSULT1A1MAPTMMP2MMP9
SCHEMBL1984367 0.88 MMP2 (0.76) APPSULT1A1MAPTMMP2MMP9
SCHEMBL12422009 0.88 MAPT (0.73) APPMAPTMMP2MMP9MMP8
SCHEMBL12422020 0.87 MAPT (0.62) APPSULT1A1MAPTLMNADYRK1A
SCHEMBL2194415 0.86 APP (0.72) APPSULT1A1MAPTMMP2MMP9
SCHEMBL2192963 0.85 APP (0.71) APPMAPTMMP2MMP9MMP8
SCHEMBL12509563 0.84 SULT1A1 (0.59) APPSULT1A1MAPTMMP2MMP9
SCHEMBL12421981 0.84 MAPT (0.74) APPSULT1A1MAPTMMP2MMP9
SCHEMBL9238817 0.84 APP (1.00) APPSULT1A1MAPT
SCHEMBL16256408 0.83 SULT1A1 (0.57) APPSULT1A1MAPTMMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180028694-A1 THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2018-02-01 US disclosed
US-20180028694-A1 THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2018-02-01 US disclosed
US-9808541-B2 Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition University of Pittsburgh—Of the Commonwealth System of Higher Eduation (US) 2017-11-07 US disclosed
US-9808541-B2 Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition University of Pittsburgh—Of the Commonwealth System of Higher Eduation (US) 2017-11-07 US disclosed
US-20150165073-A1 THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2015-06-18 US disclosed
US-20150165073-A1 THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2015-06-18 US disclosed
EP-2338059-B1 Ligands for aggregated tau molecules WISTA LAB LTD (SG) 2015-04-08 EP disclosed
EP-2338059-B1 Ligands for aggregated tau molecules WISTA LAB LTD (SG) 2015-04-08 EP disclosed
US-8911707-B2 Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2014-12-16 US disclosed
US-8911707-B2 Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2014-12-16 US disclosed
US-20080305040-A1 In Vivo or in Vitro Method For Detecting Amyloid Deposits Having at Least One Amyloidogenic Protein UNIVERSITY OF PITTSBURGH 2008-12-11 US disclosed
US-20080286202-A1 Method of Diagnosing Prodromal Forms of Diseases Associated With Amyloid Deposition UNIVERSITY OF PITTSBURGH (US) 2008-11-20 US disclosed
US-20080286202-A1 Method of Diagnosing Prodromal Forms of Diseases Associated With Amyloid Deposition UNIVERSITY OF PITTSBURGH (US) 2008-11-20 US disclosed
US-20080219931-A1 Amyloid Imaging as a Surrogate Marker for Efficacy of Anti-Amyloid Therapies UNIVERSITY OF PITTSBURGH 2008-09-11 US disclosed
US-20080219931-A1 Amyloid Imaging as a Surrogate Marker for Efficacy of Anti-Amyloid Therapies UNIVERSITY OF PITTSBURGH 2008-09-11 US disclosed
US-20080021077-A1 Bioavailability, nontoxic; 2-(3'-Iodo-4'-aminophenyl)-6-methoxybenzothiazole UNIVERSITY OF PITTSBURGH 2008-01-24 US disclosed
US-20080021077-A1 Bioavailability, nontoxic; 2-(3'-Iodo-4'-aminophenyl)-6-methoxybenzothiazole UNIVERSITY OF PITTSBURGH 2008-01-24 US disclosed
US-7270800-B2 Imaging amyloid deposits in living patients, with an amyloid binding agents having radiolabeled iodine; radiotherapy UNIVERSITY OF PITTSBURGH (US) 2007-09-18 US disclosed
US-7270800-B2 Imaging amyloid deposits in living patients, with an amyloid binding agents having radiolabeled iodine; radiotherapy UNIVERSITY OF PITTSBURGH (US) 2007-09-18 US disclosed
WO-2007035405-A2 IN-VIVO AND IN-VITRO METHOD FOR DETECTING AMYLOID DEPOSITS HAVING AT LEAST ONE AMYLOIDOGENIC PROTEIN UNIVERSITY OF PITTSBURGH (US) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180028694-A1 THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION APP, PSEN2, MAPT APP 1/4885SULT1A1 642/4885MAPT 3/4885
US-20150165073-A1 THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION APP, PSEN2, MAPT APP 1/4885SULT1A1 642/4885MAPT 3/4885
US-20080021077-A1 Bioavailability, nontoxic; 2-(3'-Iodo-4'-aminophenyl)-6-methoxybenzothiazole APOL1, APOB, APP APP 3/4885SULT1A1 639/4885MAPT 6/4885
US-20080219931-A1 Amyloid Imaging as a Surrogate Marker for Efficacy of Anti-Amyloid Therapies TTR, APP, SAAL1 APP 2/4885SULT1A1 2536/4885MAPT 14/4885
US-20080286202-A1 Method of Diagnosing Prodromal Forms of Diseases Associated With Amyloid Deposition PSEN2, PSEN1, APP APP 3/4885SULT1A1 4158/4885MAPT 13/4885
US-20080305040-A1 In Vivo or in Vitro Method For Detecting Amyloid Deposits Having at Least One Amyloidogenic Protein TTR, APBA1, APP APP 3/4885SULT1A1 3850/4885MAPT 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.